[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,130
Citations 0
Correction
July 19, 2016

Update in Conflict of Interest Disclosure and Errors in the Supplement and Figure

JAMA. 2016;316(3):350. doi:10.1001/jama.2016.6123

In the Original Investigation entitled “Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention,” published in the April 26, 2016, issue of JAMA,1 a conflict of interest disclosure needs to be updated. The disclosures for Drs Yeh and Mauri state that they have “a pending patent for development and use of the DAPT Score.” They have withdrawn this patent application since the article has been published and this disclosure has been removed from their disclosures. Also, due to an errant font, the Supplement had question marks in an eTable and an eFigure instead of the proper information. An updated Supplement has been provided. The bar graph in Figure 2 had the incorrect frequencies. This article was corrected online.

References
1.
Yeh  RW, Secemsky  EA, Kereiakes  DJ,  et al; DAPT Study Investigators.  Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735-1749.
PubMedArticle
×